Veeva Systems acquires Israeli clinical trial AI startup Yonalink
What's the deal? Veeva Systems, a US cloud software provider for the life sciences industry with a $26B market cap, has acquired Israeli startup Yonalink for an undisclosed sum. Yonalink's 20 employees will join Veeva as part of the deal.
Yonalink built an AI platform that automates the transfer of data from medical records to clinical research while maintaining data security and privacy rules. This process was previously done manually — slow, labour-intensive, and error-prone.
Founded in 2020 by CEO Iddo Peleg and VP of business development Gav Martell, Yonalink had raised $10M from investors including Swiss pharma company Debiopharm, eHealth Ventures, and the EU's Horizon programme. Its main market is the US.
Why now? Yonalink says Veeva made a direct approach to Peleg, and the deal progressed quickly despite security tensions and the recent war with Iran. The company had already built momentum — starting with a pilot at Sheba Hospital in Tel Hashomer through the Israel Innovation Authority's pilot programme, then expanding to most medical centres in Israel and beyond.
"Connecting with Veeva is the most natural step for us to bring the message of automation to every research center in the world," Peleg said.
What could go wrong? Integrating a 20-person startup into a $26B enterprise is never seamless. Yonalink's technology must scale across Veeva's vast global client base without compromising the data security and privacy standards that are central to its value proposition.
The undisclosed deal terms also make it hard to gauge whether investors saw a meaningful return on the $10M raised.
The signal: Veeva's acquisition of a five-year-old, 20-person startup underscores how large life sciences platforms are moving aggressively to embed AI-driven automation into clinical trial workflows — a space where manual data handling has long been a costly bottleneck. For Veeva, still classified as a late growth-stage company on Dealroom despite its $26B market cap, bolt-on acquisitions like this are a faster route to differentiation than building in-house, particularly as competition intensifies to digitise the clinical research pipeline end to end.
Read more: en.globes.co.il
